News

Avammune Therapeutics raises $12 million to advance cancer therapies

Publications

Small molecule innate immune modulators in cancer therapy
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb, Aditya Kulkarni

PMID: 39318624 PMCID: PMC11419979 DOI:10.3389/fimmu.2024.1395655

AVA-ADR-001 Suppresses Tumor Growth and Induces Anti-tumor Immunity by Selectively Inhibiting ADAR1 p150
Aditya Kulkarni, Avijit Goswami, Barnali Deb, Ankita Mohanty, Sandeep Goyal, Kawaljit Singh, Rahul Yadav, Princy Khurana, Narenkumar Muralidharan, Jan Rehwinkel

Molecules 2022,27(19), 6721; DOI: 10.3390/molecules27196721

Conference Abstracts

809 Exploring the therapeutic benefit of AVA-NP-695 (ENPP1 inhibitor) and DNA damage inhibition to activation of the immune system in metastatic osteosarcoma
Borja Ruiz Fernandez de Cordoba, Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Aditya Kulkarni, Alejandro Sweet-Cordero

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 2) A914; DOI:10.1136/jitc-2024-SITC2024.0809

740 Discovery of a potential first-in-class inhibitor targeting ADAR1 p150 isoform with strong anti-tumor efficacy in syngeneic melanoma mouse model
Avijit Goswami, Sandeep Goyal, Kawaljit Singh, Princy Khurana, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2024, 12 (Suppl 2) A843; DOI:10.1136/jitc-2024-SITC2024.0740

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics